Cetuximab (EGFR) - Onderzoeksklasse Biosimilar

Cetuximab is an epidermal growth factor receptor binding FAB.Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.Cetuximab is marketed under the brand Erbitux® by Eli Lilly and Company.In the United States, a regimen of cetuximab costs approximately $30,790 for an eight-week course.Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers.Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.

Chimeric / EGFR [Homo sapiens]

Unconjugated

Primary Antibodies, Biosimilars

CHO cells

Cancer

>95%

Batch dependent

PBS buffer pH7.5

None

Blue Ice

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

IgG1-kappa

Homo sapiens

Fab C225, IMC-225